摘要
Abstract
Objective To systematically evaluate the randomized controlled trials of S - 1 or fluorouracil for the treatment of advanced gastrointestinal cancer. Method Literature was retrieved from Cochrane Library, MEDLINE, EMBase, Tompson SCI, VIP and other databases, and the results were analyzed using RevMan 5. 1. 2 software package. Results Four studies were obtained for this analysis. It was found that S - 1 improved the overall survival up to 24 months [ RR = 1. 45 , 95% CI ( 1. 05 , 2. 00 ), I = 0, P = 0. 02 ] , but failed to improve the overall survival and the disease - free survival. The effect of S -1 over neutrophils was significantly less than that of flurouracil [ RR = 0. 75, 95% CI ( 0. 70, 0. 80 ), I2 = 0, P < 0. 00001 ]. S - 1 had little effect on grade 3-4 thrombocytopenia [ RR = 0. 60, 95% CI ( 0. 43, 0. 84 ), I2 = 0% , P = 0. 003 ]. The effects of S - 1 on diarrhea, nausea, creatinine clearance rate, bone marrow, and blood levels of potassium, phosphorus, and magnesium were low but had a high effect on bilirubin when compared with fluorouracil [ RR = 2. 08, 95% CI (1.49, 2. 91), I =0, P <0. 0001 ]. Conclusion S - 1 can not prolong disease - free survival and overall survival in patients with advanced gastrointestinal cancer. Compared with fluorouracil, S - 1 can lower the adverse effects of the drugs over bone marrow, blood cells ( especially neutrophils and platelets ), and gastrointestinal symptoms such as nausea and diarrhea, although with less effect on bilirubin.关键词
替吉奥/氟尿嘧啶/消化系统肿瘤/化学疗法Key words
S - 1/ Fluorouracil/ Digestive system neoplasms/ Chemotheraphy分类
医药卫生
